Print

Communication on biosimilar medicines

 

 

 

The era of biological medicines
Since their first use in the 1980s, biological medicines (including biosimilar medicines) have grown to become an indispensable tool in modern medicine. Worldwide, millions of patients have already benefited from approved biological medicines, but what exactly are they, and how are they produced?

Open

 



Biological medicines ― the major social and economic challenges

The global spend on pharmaceuticals continues to increase. The use of biological medicines offers new treatment choices to patients, but at a high financial cost. What are the challenges faced by payers and physicians in preserving access to biological medicines within a financially constrained healthcare system?

Open

 



Biosimilar medicines — rising to the cost challenge

Addressing the rising cost of biological medicines has become a priority for governments and healthcare systems around the globe.
Biosimilar medicines are providing more cost-effective biological treatments, but what are biosimilar medicines, and how do they meet this challenge?

Open

 



Biosimilar medicines — a commitment to scientific excellence

With biosimilar medicines, patients and healthcare providers benefit from high quality and efficacious therapeutic alternatives.
But how are biosimilar medicines developed, and how is their efficacy and safety ensured?

Open

 



The benefits of biosimilar medicines
Biosimilar medicines have demonstrated similarity with reference biologicals in terms of structure, function, safety and efficacy, but what are their benefits?

Open

 



Building on the experience and success of biosimilar medicines

Biosimilar medicines are increasingly becoming an integral part of modern healthcare systems, so what does the future hold?

Open

If you wish to use any part of this slide deck, please contact us at This email address is being protected from spambots. You need JavaScript enabled to view it. . We would be happy to share this with you.

Contact Info

IGBA | INTERNATIONAL GENERIC AND BIOSIMILAR MEDICINES ASSOCIATION

Rue d'Arlon, 50
B-1000 Brussels, Belgium

Telephone: +32 (0)2 736 84 11
Fax: +32 (0)2 736 74 38
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.